ESR1 and neoplasm: Simultaneous inhibition of menin, DOT1L, and BAZ1B synergistically slows the proliferation of both antiestrogen-sensitive and -resistant ER-positive cell lines [275], further supporting menin’s function as a tumor promoter through its association with epigenetic modifiers.